Pathogen reduction in blood products: What's behind these techniques?

Transfusion Medicine and Hemotherapy

Volumn 38, Issue 1, 2011, Pages 5-6

  Janetzko, Karin ^a   Bugert, Peter ^b  

^a University of Ulm   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; GENOMIC DNA; GENOMIC RNA; HEPATITIS ANTIGEN; HEPATITIS B VIRUS ANTIGEN; METHYLENE BLUE; RIBOFLAVIN; UNCLASSIFIED DRUG;

ANTIBODY SCREENING; BACTERIUM CONTAMINATION; BLOOD DONOR; BLOOD SAFETY; BLOOD STORAGE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CELL FUNCTION; DISEASE TRANSMISSION; EBOLA HEMORRHAGIC FEVER; EDITORIAL; ERYTHROCYTE; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFLUENZA VIRUS A H5N1; LEUKOCYTE; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MORTALITY; PARVOVIRUS; PATHOGEN REDUCTION; RISK ASSESSMENT; RISK REDUCTION; SEVERE ACUTE RESPIRATORY SYNDROME; SYPHILIS; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION ASSOCIATED HEPATITIS B; TRANSFUSION ASSOCIATED HEPATITIS C; TRANSFUSION RELATED ACUTE LUNG INJURY; ULTRAVIOLET A RADIATION; ULTRAVIOLET C RADIATION; ULTRAVIOLET RADIATION; VIRUS GENOME; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 79851488461     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324457     Document Type: Editorial

References (17)

1. Beeson PB: Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA 1943;121:1332-1334.
2. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group: Experience of Ger-man Red Cross blood donor services with nucleic acid testing: results of screening more than 30 mil-lion blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;48:1558-1566.
3. Woolhouse ME: Population biology of emerging and re-emerging pathogens. Trends Microbiol 2002; 10(suppl):S3-7.
4. Dodd RY, Leibly DA: Emerging infectio (Pubitemid 38316723)
5. Barbara J: Why 'safer then ever' may not be quite safe enough. Transfus Med Hemother 2004;349: 1236-1245.
6. Schrezenmeier H, Walther-Wenke G, Müller TH, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Förstemann E, Gebauer W, Höchsmann B, Kara-kassopoulos A, Liebscher UM, Sänger W, Schmidt M, Schunter F, Sireis W, Seifried E: Bacterial con-tamination of platelet concentrates: results of a pro-spective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007;47:644-652. (Pubitemid 46449625)
7. Perez P, Salmi LR, Follea G, Schmit JL, de Bar-beyrac B, Sudre P, Salamon R, BACTHEM group, French Haemovigilance Network: Determinants of transfusion-associated bacterial contamination: Re-sults of the French BACTHEM Case-Control Study. Transfusion 2001;41:862-872 (Pubitemid 32642757)
8. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR: Transfusion transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41:1493-1499 (Pubitemid 34072672)
9. Schmidt M, Hourfar MK, Nicol SB, Wahl A, Weis C, Tonn T, Sprengler HP, Montag T, Seifried E, Roth WK: A comparison of three rapid bacterial detection methods under simulated real-life condi-tions. Transfusion 2006;46:1367-1373 (Pubitemid 44117965)
10. Dreier J, Vollmer T, Kleesiek K: Novel flow cytom-etry-based screening for bacterial contamination of donor platelet preparations compared with other rapid screening methods. Clin Chem 2009;55:1492-1502
11. Walter-Wenke G, Schrezenmeier H, Deitenbeck R, Geis G, Burkhart J, Höchsmann B, Sireis W, Schmidt M, Seifried E, Gebauer W, Liebscher UM, Weinauer F, Müller TH: Screening of platelet con-centrates for bacterial contamination: spectrum of bacterial detection, proportion of transfused units, and clinical follow up. Ann Hematol 2009; DOI: 10.1007/s00277-009-0762-2.
12. Marschner S, Goodrich RP: Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Trans-fus Med Hemother 2011;38(1):8-18.
13. Irsch J, Lin L: Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother2011;38(1):19-31.
14. Henschler R, Seifried E, Mufti N: Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38(1):33-42.
15. Seltsam A, Müller TH: UVC irradiation for patho-gen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011;38(1):43-54.
16. Seghatchian J, Struff WG, Reichenberg S: Main properties of the THERAFLEX MB-plasma sys-tem for pathogen reduction. Transfus Med He-mother 2011;38(1):55-64.
17. Hellstern P, Solheim BG: The use of solvent/deter-gent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011;38(1):65-70.